EarningsQ4 2026 Earnings Report

Cardinal Health (CAH) Q4 2026 Earnings Report

0 Followers

Previous Report: Q3 2026

MX:CAH Q4 2026 EPS Results

Actual EPS$52.59

Consensus EPS$43.74

Beat/MissBeat by +$8.86

One Year Ago EPS$37.59

MX:CAH Q4 2026 Revenue Results

Actual Revenue$1.15T

Expected Revenue$1.18T

Beat/MissMissed by -$26.77B

YoY Revenue Growth+5.84%

Earnings Announcement Details

QuarterQ4 2026

Date08/11/2026

TimeBefore Open

Conference CallTuesday, August 11, 2026

MX:CAH Upcoming Earnings

Cardinal Health's next earnings date is estimated for November 5, 2026, based on past reporting schedules.

Q4 2026 Earnings Call Audio

MX:CAH Q4 2026 Earnings Call

0:00 / 0:00

Q4 2026 Earnings Slide Deck

Q4 2026 Earnings Call Summary

Q4 2026

Earnings Call Date:Aug 11, 2026|

% Change Since:

Earnings Call Sentiment|Positive

The call emphasized strong, broad-based fiscal '26 performance across revenue, profit, EPS (Q4 EPS +40% YoY) and cash flow ($5B adjusted FCF), with clear operational momentum in Pharma, Specialty and Other growth businesses and disciplined capital return (share buybacks and increased repurchase authorization). Key risks highlighted include reliance on a nonrecurring $100M IEEPA tariff refund that materially boosted GMPD profitability and $0.31 of Q4 EPS, input cost pressures (fuel and commodity resins), regulatory headwinds (IRA/340B impacts ~500 bps mentioned), and expected near-term cadence softness (Q1 FY27 headwind). Overall, positives around scale, cash generation, segment momentum and reconfirmed long‑term targets materially outweigh the transitory and manageable challenges discussed.

Company Guidance

Cardinal guided fiscal 2027 non‑GAAP EPS of $12.40–$12.60 (13–15% growth off a $10.95 baseline that excludes the $0.31 IEEPA tariff benefit) and reconfirmed long‑term EPS growth of 12–14% per year; segment guidance calls for Pharma revenue growth of 3–5% and Pharma profit growth of 8–11% (with 2–3 percentage points of profit contribution from announced M&A and Q1 Pharma profit expected near the high end due to Solaris), GMPD revenue growth of 2–4% and segment profit of $200–$220 million (≈$50M growth ex‑IEEPA, H2‑weighted with Q1 roughly half of prior Q1 on FX and purchase timing), and Other businesses revenue growth of 11–13% with profit up 15–18% (including ~2 points of profit from the Strive and AdaptHealth tuck‑ins); below the line, interest and other expense is expected to be $240–$290M, the effective tax rate 19–20%, adjusted free cash flow $3.5–$4.0B, CapEx ~$700M, at least $1B of share repurchases (implying ~233M diluted shares), no material M&A assumed but modest tuck‑in capacity retained, and liquidity supported by a new $4B revolver.

Strong FY26 Financial Results

Full-year revenue $254B (+14% YoY); gross margin $9.8B (+20% YoY); total operating earnings $3.6B (+30% YoY); adjusted free cash flow $5.0B for the year.

Q4 Consolidated Performance

Q4 revenue $63.7B (+6% YoY); gross profit $2.6B (+16% YoY); consolidated operating income $935M (+30% YoY); diluted EPS $2.91 in Q4 (+40% YoY).

Pharmaceutical & Specialty Strength

Pharma segment Q4 revenue $58.8B (+6% YoY) and segment profit $645M (+21% YoY); Specialty delivered double-digit growth for the year and was a primary driver of enterprise results.

Other Growth Businesses Momentum

Other segment Q4 revenue $1.7B (+7% YoY) and segment profit $183M (+14% YoY); Nuclear/PET grew rapidlty—PET >20% and Theranostics ~30% in the quarter (over 30% for FY26); Other guided to revenue growth of 11%–13% and profit growth of 15%–18% in FY27.

GMPD Profit Improvement (Including One-time Benefit)

GMPD segment profit increased by $80M in Q4 to $150M, reflecting operational progress and recording a one-time net $100M IEEPA tariff refund benefit (company views refund as nonrecurring).

Balance Sheet, Liquidity and Capital Return

Ended FY26 with $4.9B cash on hand, generated $5B adjusted free cash flow, completed $1.35B share repurchases in FY26 (average price $187), announced at least $1B repurchase plan for FY27 and Board authorization increase of $5.0B (total $6.4B).

Reconfirmed Long-Term and FY27 Guidance

Reconfirmed long-term EPS CAGR target 12%–14%; FY27 EPS guidance $12.40–$12.60 (13%–15% growth off baseline), FY27 adjusted free cash flow guidance $3.5B–$4.0B; segment-level guidance provided (Pharma revenue 3%–5%, Pharma profit 8%–11%, GMPD revenue 2%–4%).

MX:CAH Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change
Nov 05, 2026	2027 (Q1)	53.30 / -	46.087	―
Aug 11, 2026	2026 (Q4)	43.74 / 52.59	37.593	39.90% (+15.00)
Apr 30, 2026	2026 (Q3)	50.52 / 57.29	42.472	34.89% (+14.82)
Feb 05, 2026	2026 (Q2)	42.31 / 47.53	34.882	36.27% (+12.65)
Oct 30, 2025	2026 (Q1)	39.44 / 46.09	33.978	35.64% (+12.11)
Aug 12, 2025	2025 (Q4)	36.82 / 37.59	33.255	13.04% (+4.34)
May 01, 2025	2025 (Q3)	39.29 / 42.47	37.593	12.98% (+4.88)
Jan 30, 2025	2025 (Q2)	32.26 / 34.88	32.894	6.04% (+1.99)
Nov 01, 2024	2025 (Q1)	29.26 / 33.98	31.267	8.67% (+2.71)
Aug 14, 2024	2024 (Q4)	31.34 / 33.26	28.014	18.71% (+5.24)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed